

**APC914Hu01 100µg**  
**Active Fibroblast Growth Factor 12 (FGF12)**  
**Organism Species: *Homo sapiens* (Human)**  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

13th Edition (Revised in Aug, 2023)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Met1~Thr181

**Tags:** N-terminal His-tag

**Purity:** >95%

**Endotoxin Level:** <1.0EU per 1µg (determined by the LAL method).

**Buffer Formulation:** PBS, pH7.4, containing 0.01% SKL, 5%Trehalose .

**Original Concentration:** 200µg/mL

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 8.6

**Predicted Molecular Mass:** 24.1kDa

**Accurate Molecular Mass:** 25kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## [ SEQUENCE ]

```
MEKSEFQLKGI VTRLFSQQGYFLQMHPDGTIDGTDKDNSDYTLFNLIPVGLRVVAIQGVKASLYVAMNGEGLYSSDVFTPECKFKBSVFNYYVIHS  
STLYRQQESGRAWFLGLNKEGQIMKGNRVKKTTPSSHPVFKPIEVCMYREPSLHEIGEKQGRSRKSSGPTMNGGKVVNQDST
```

## [ ACTIVITY ]

Fibroblast Growth Factor 12 (FGF12) is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth, and invasion. Fibroblast Growth Factor 12 (FGF12) may represent an important modulator of neuronal network activity and has been associated with developmental and epileptic encephalopathy (DEE). Besides, it is reported that both domains of (Ca<sup>2+</sup>)<sub>4</sub>-CaM directly bind two sites in the N-terminal domain (NTD) of A-type FGF splice variants (FGF11A, FGF12A, FGF13A, and FGF14A) with high affinity. Calmodulin 1 (CALM1) has been identified as an interactor of FGF12, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF12 and recombinant human CALM1. Briefly, FGF12 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to CALM1-coated microtiter wells and incubated for 1h at 37 °C. Wells were washed with PBST and incubated for 1h with anti-FGF12 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37 °C, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The

binding activity of recombinant human FGF12 and recombinant human CALM1 was shown in Figure 1, the EC50 for this effect is 4.44 ug/mL.




Figure 1. The binding activity of recombinant human FGF12 and recombinant human CALM1

## [ IDENTIFICATION ]




Figure 2. SDS-PAGE

Sample: Active recombinant FGF12, Human

## [ IMPORTANT NOTE ]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.